NF1 inactivation leads to MAPK activation, and NF1 mutations are observed in older patients, desmoplastic melanoma, and males. NF1-mutated melanomas exhibit increased sensitivity to MEK inhibitors. This evidence concerns the gene NF1 and melanoma.